Alopecia areata : An appraisal of new treatment approaches and overview of current therapies - 13/12/17
![](/templates/common/images/mail.png)
Abstract |
Many therapies are available for the treatment of alopecia areata, including topical, systemic, and injectable modalities. However, these treatment methods produce variable clinical outcomes and there are no currently available treatments that induce and sustain remission. When making management decisions, clinicians must first stratify patients into pediatric versus adult populations. Disease severity should then be determined (limited vs extensive) before deciding the final course of therapy. The second article in this continuing medical education series describes the evidence supporting new treatment methods, among them Janus kinase inhibitors. We evaluate the evidence concerning the efficacy, side effects, and durability of these medications. An overview of conventional therapy is also provided with new insights gleaned from recent studies. Finally, future promising therapeutic options that have not yet been fully evaluated will also be presented.
Le texte complet de cet article est disponible en PDF.Key words : alopecia areata, alopecia totalis, alopecia universalis, corticosteroids, JAK inhibitors, minoxidil, topical immunotherapy
Abbreviations used : AA, AT, AU, DPCP, JAK, SADBE, SALT, TAC
Plan
Funding sources: None. |
|
Dr Shapiro is a consultant for Aclaris Therapeutics, Applied Biology, Incyte, Replicel Life Sciences, and Samumed. Dr Christiano is a consultant for Aclaris Therapeutics and a principal investigator for Pfizer. The other authors have no conflicts of interest to declare. |
|
Ms Strazzulla and Dr Wang contributed equally to this article. |
|
Date of release: January 2018 |
|
Expiration date: January 2021 |
Vol 78 - N° 1
P. 15-24 - janvier 2018 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?